Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emergent Broadens Bioterror Offering In $125m Sanofi Smallpox Vaccine Buy

Executive Summary

Sanofi's divestment of its ACAM200 smallpox vaccine frees it to focus on "current and emerging" infectious disease jabs - while expanding Emergent BioSolutions adds to its anti-bioterror product offering.

You may also be interested in...



Deal Watch: Valeant Continues Divestment Spree By Selling Obagi At A Loss

Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval

Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel